-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
-
Summary
-
Vertex Pharmaceuticals Inc / Ma quarterly/annual Income Tax Expense (Benefit) history and growth rate from 2010 to 2023.
- Vertex Pharmaceuticals Inc / Ma Income Tax Expense (Benefit) for the quarter ending September 30, 2024 was $179M, a 24.2% increase year-over-year.
- Vertex Pharmaceuticals Inc / Ma Income Tax Expense (Benefit) for the twelve months ending September 30, 2024 was $739M, a 11.9% decline year-over-year.
- Vertex Pharmaceuticals Inc / Ma annual Income Tax Expense (Benefit) for 2023 was $760M, a 16.5% decline from 2022.
- Vertex Pharmaceuticals Inc / Ma annual Income Tax Expense (Benefit) for 2022 was $910M, a 134% increase from 2021.
- Vertex Pharmaceuticals Inc / Ma annual Income Tax Expense (Benefit) for 2021 was $388M, a 4.17% decline from 2020.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Growth (%)